Article info
Ovarian cancer
1025 Revisiting the Rotterdam regime in 2021: the impact of cisplatin and oral etoposide in refractory ovarian cancer in the era of great antiemetics
Citation
1025 Revisiting the Rotterdam regime in 2021: the impact of cisplatin and oral etoposide in refractory ovarian cancer in the era of great antiemetics
Publication history
- First published October 12, 2021.
Online issue publication
October 12, 2021
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.